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Nowadays, colorectal cancer prevention strategies play an essential role in
reducing the incidence and mortality of the cases. A well-designed and establish-
ment of the clinical pathway of screening programme needed in all country. Types
of screening tools used may vary between the country with the use of FOBT and
colonoscopy. The standard guideline related to screening programme such as for
high-risk group should be emphasized more as compared to the low-risk group.
The uptake of screening for CRC should be highlighted more as the program have
showed a significantly reduction of the cases and mortality. The barrier of CRC
screening uptake mainly due to poor awareness, discomfort, low physician recom-
mendation, low socioeconomic and improper screening programme. Therefore
others prevention strategies beside screening program such as health education and
interactive intervention strategies need to be empower.
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1. Introduction
Colorectal cancer (CRC) incidence and mortality rates vary across worldwide,
with distinct gradients across human development levels were seen, pointing
towards an increasing burden in countries in transition. In general, CRC incidence
and mortality rates are still rising rapidly in many low-income and middle-income
countries, particularly in Eastern Europe, Asia, and South America. While stabiliz-
ing or decreasing trends are seen in highly developed countries such as Japan, the
United States and Australia, where rates remain among the highest in the world [1].
CRC mortality can be reduced if cases are detected and treated early. When
identified early, CRC is more likely to respond to effective treatment and can result
in a greater probability of surviving, less morbidity, and less expensive treatment.
On the other hand, CRC screening aims to identify individuals with abnormalities
suggestive of cancer or pre-cancer who have not developed any symptoms and to
refer them for diagnosis and treatment. Nonetheless, a screening program is a far
more complex public health intervention compared to early diagnosis [2].
2. Colorectal cancer screening programs
CRC screening programs are currently underway in most European countries,
Canada, specific regions in North and South America, Asia, and Oceania. The most
comprehensive screening strategies were based on fecal occult blood testing, and
more recently, the fecal immunochemical test (FIT) [3]. While other options for
CRC screening are fecal immunochemical test annually, guaiac-based fecal occult
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blood test annually, multi-target stool DNA test every three years, colonoscopy
every ten years, computed tomography colonography every five years, and flexible
sigmoidoscopy every five years [4].
CRC screening programs are designed for populations according to risk stratifi-
cation. In general population-based screening, these programs are offered to the
Figure 1.
Clinical pathway of screening for colorectal carcinoma. Source: Kamil et al. [6].
Figure 2.
Risk categories for family history with CRC. Source: Kamil et al. [6].
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population with average risk. While in a certain country, opportunistic CRC
screening is provided at primary healthcare centres, also catering those with aver-
age risk. Therefore, most uptakes are due to routine recommendation offered by
attending doctors, despite low.
Most of the significant CRC guidelines recommend screening of CRC to start at
the age of 50 years old. For instance, the US Preventive Task Force recommends
screening for CRC to begin at the age of 50 years and continues until age 75 years.
The decision to screen for CRC in adults aged 76 to 85 years should be individual-
ized, taking into account the patient’s overall health and prior screening history [5].
For examples, according to Malaysian guideline, screening of colorectal carcinoma
(CRC) should be offered at the age of 50 years and continues until age 75 years for
the average-risk population. Immunochemical fecal occult blood test (iFOBT) is the
preferred method to screen for CRC in an average-risk community. If iFOBT is
positive, an early colonoscopy is necessary. Whereas, if iFOBT is negative, the
yearly test should be performed (Figures 1 and 2) [6].
These screening tests are not only effective in the early discovery of malignant
tumors, but also serves as a preventive procedure whereby polyps that could
potentially become malignant can be found and removed before becoming
cancerous [2].
3. Colorectal cancer screening modalities
There were several screening tests available for CRC which vary in terms of their
performance accuracy, complication rates, screening uptake as well as costs associ-
ated with screening. Among several options available are fecal occult blood test
(FOBT), flexible sigmoidoscopy (FS), colonoscopy, colon capsule endoscopy
(CCE), and computed tomographic colonography (CTC).
3.1 Fecal test
Fecal test is a non-invasive tool for CRC screening in general population. It can
detect presence of blood, proteins e.g. enzyme M2-PK and DNA. Fecal occult blood
refers to blood in the feces that is not visibly apparent. A fecal occult blood test
(FOBT) is designed to identify hidden or small quantities of blood in fecal sample.
There are two main types of FOBTs: guaiac-based fecal occult blood test (gFOBT)
and immunochemical fecal occult blood test (iFOBT) which is also known as fecal
immunochemical test (FIT).
FOBT has qualitative and quantitative testing methods. In a meta-analysis of fair
to high quality evidence, the pooled sensitivity to detect CRC was 74% (95% CI
62-83) for quantitative test methods and 79% (95% CI 61-90) for qualitative test
methods [5]. Immunochemical FOBT (iFOBT) and guaiac-based FOBT (gFOBT)
are two methods of qualitative FOBT. The sensitivities of iFOBT and gFOBT are
0.67 (95% CI 0.61-0.73) and 0.54 (95% CI 0.48-0.60) respectively. The specificities
of iFOBT and gFOBT are comparable at 0.85 (95% CI 0.83-0.87) and 0.80 (95% CI
0.78-0.82) respectively [7].
Overall, screening with FOBT (either iFOBT or gFOBT) has a 16% reduction in
the risk of CRC mortality (RR = 0.84, 95% CI 0.78-0.90) as compared to unscreened
population [8], while screening with iFOBT can reduce CRC mortality by 22% as
compared to screening with gFOBT [9].
Other fecal test include fecal M2-PK enzyme detection and fecal DNA tests.
Fecal M2-PK has a pooled sensitivity and specificity of 79% (95% CI 73 to 83) and




test has a higher sensitivity at 92% (95% CI 84 to 97) to detect CRC [5]. These two
fecal tests for CRC screening are, however, not widely used locally in screening for
general population due to high cost incurred.
3.2 Flexible sigmoidoscopy (FS)
FS needs less rigorous bowel preparation and can be performed as a clinic-based
procedure without the need for sedation. Small polyps can be biopsied during
procedure but excision of larger lesions (>1 cm) may be performed during subse-
quent colonoscopy.
In two randomized controlled trial studies conducted in the United States and
the United Kingdom, sigmoidoscopy reduces the CRC incidence by 18-26% and
mortality by 26-30% in general population. The reduction in mortality, however,
was limited to distal colon, with no significant effect in the proximal colon [11–12].
3.3 Colonoscopy
Colonoscopy is the screening modality that has the ability to visualize the colonic
mucosa directly, perform biopsy and excise polyps. It can detect proximal lesions
that would be missed by screening sigmoidoscopy and has been shown to reduce
risk of cancer in the right colon, while for those who has had colonoscopy especially
for screening, the risk of CRC is strongly reduced by 91% up to 10 years [13]. In
different study, it was also found that screening colonoscopy was associated with a
substantial and comparably decreased mortality risk for both right-sided (65%
reduction) and left-sided (75% reduction) cancers within a large community-based
population [14].
According to the American College of Gastroenterology Guidelines, the pre-
ferred CRC prevention test (screening test) with strong recommendation is colo-
noscopy every 10 years, beginning at age of 50 based on the evidence of
effectiveness, cost-effectiveness and acceptance by patients [15]. The National
Cancer Comprehensive Network Clinical Practice Guidelines for Colorectal Cancer
Screening also stated that colonoscopy is currently the preferred screening method.
It is also the required procedure for confirmation of positive findings from other
screening tests [16].
However, based on the updated Asia Pacific Consensus on Colorectal Cancer
report in 2013, colonoscopy is recommended for those with an increased risk of
CRC based upon the family history of CRC and other related risk factors for CRC.
This recommendation has been suggested by the panel in view of colonoscopy being
an invasive, labour intensive and more expensive method for CRC screening [17].
3.4 Colon capsule endoscopy (CCE)
CCE is used to obtain images of the colon by using video cameras embedded in
an ingested capsule. The technique is less invasive but does not allow biopsy or
polyp removal.
The sensitivity in detection of polyps >6 mm and > 10 mm increased substan-
tially between development of first-generation (CCE-1) and second-generation
(CCE-2) of CCE. CCE-2 and CCE-1 detect polyps >6 mm with sensitivity of 86%
(95% CI 82–89%) and 58% (95% CI 44–70%) respectively, and specificity of 88.1%
(95% CI 74.2%–95.0%) and 85.7% (95% CI 80.2%–90.0%) respectively. While for
larger polyps >10 mm, CCE-2 and CCE-1 had sensitivity of 87% (95% CI 81–91%)
and 54% (95% CI 29–77%) respectively, and specificity of 95.3% (95% CI, 91.5%–
97.5%) and 97.4% (95% CI 96.0%–98.3%) respectively [18]. These high specificity
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values for detection of polyps by CCE seem to be achievable with a 10-mm cutoff
and in a screening setting.
3.5 Computed tomographic Colonography (CTC)
CTC uses multiple thin slice computed tomographic data to construct images of
the bowel mucosa in two or three dimensions in detecting polyps. It requires bowel
preparation similar to conventional colonoscopy and during the procedure, air or
carbon dioxide is introduced into the rectum via a rubber catheter. No sedation is
required and patient is usually able to return to work post procedure.
Estimated sensitivities for patients with polyps or adenomas ≥6 mm were 75.9%
(95% CI 62.3–85.8) and 82.9% (95% CI 73.6–89.4), with corresponding specificities
94.6% (95% CI 90.4–97.0) and 91.4% (95% CI 84.1–95.5) respectively. On the other
hand, estimated sensitivities for patients with polyps or adenomas ≥10 mm were
83.3% (95% CI 76.8–89.0) and 87.9% (95% CI 82.1–92.0), with corresponding spec-
ificities 98.7% (95% CI 97.6–99.3) and 97.6% (95% CI 95.0–98.9) respectively [19].
The major drawbacks of CTC are that it is non-therapeutic, with the need for
colonoscopy after the identification of polyps for excision and tissue diagnosis.
Other reasons include argument for radiation exposure, presence of flat adenomas
that are more likely to be missed by CTC than colonoscopy, and issues of incidental
extra-colonic pathological findings that may arise [19, 20].
4. Colorectal cancer screening uptake
Participation in screening has varied greatly among different regions. The Neth-
erlands showed the highest participation rate (68.2%) and some areas of Canada
showed the lowest (16%). Participation rates were highest among women and in
programs that used the iFOBT test. The iFOBT test has been the most widely test
used in screening program worldwide nowadays. The advent of this test has
increased participation rates and the detection of positive results [13].
In a large scale study conducted in Asia Pacific region, 27% of respondents aged
50 years and older had undergone previous CRC testing; the Philippines (69%),
Australia (48%), and Japan (38%) had the highest participation rates, whereas India
(1.5%), Malaysia (3%), Indonesia (3%), Pakistan (7.5%), and Brunei (13.7%) had
the lowest rates [21].
5. Barriers for colorectal cancer screening
Community with cancer tends to present to cancer services in the later stages of
the disease, and this late presentation has severe, often fatal, consequences. There-
fore, increasing awareness about cancer signs and symptoms could contribute to
earlier presentation and improvements in cancer outcomes Despite the prevalence
of colorectal cancer and the many screening tests available, the number of people
going for these screening tests are very low [22]. This is rather alarming and many
studies have been conducted worldwide to discover and analyze the causes of low
turnout for colorectal cancer screening [23].
5.1 Poor knowledge of CRC symptoms and risk factors
A majority of the studies found that the largest barrier towards colorectal cancer




symptoms and screening tests available for CRC. A recent multi-center, interna-
tional study involving 14 countries or regions in the Asia Pacific region reported
considerable deficiencies in knowledge of CRC symptoms and risk factors, and
suggested that this could lead to poor uptake of CRC screening tests. One research
indicates that there is a lack of awareness among community about CRC symptoms,
i.e. only 40.6% of 2379 participants recognized ‘blood in stool’ as a warning sign for
CRC. Other causes of delayed detection and diagnosis include denial, negative
perceptions of the disease, the over-reliance on traditional medicine, misperceived
risk, emotional barriers and negative perceptions towards screening. Cancer
awareness campaigns and their evaluation are sparse in low- and middle-income
countries.
Studies from Hong Kong, Australia and USA also reported low levels of
knowledge of CRC [22]. Other than that, those with poor educational backgrounds
are more likely to have language and communication barriers, and have a harder
time understanding materials or recommendations. Also identified being the male
gender to have poorer CRC knowledge, as females have better health knowledge
due to their traditional role as carers. With particular focus to a multiracial
country, the language barrier becomes a prominent problem. Subjects have
complained of the limited language diversity in cancer screening awareness
material, hence result in poorer understanding. This in particular would be a
problem for the older generation, as many are less multilingual than the younger
generation; and this becomes a large problem as CRC has a higher prevalence
among those above 50 years of age [23]. Few Asian countries have established
nationwide CRC awareness and screening programs, with Taiwan, Korea,
Singapore and Japan being the only Asian countries that have existing national
CRC screening guidelines and programs [23].
5.2 Lack of physician’s recommendation
Another major factor of poor knowledge within the population is the severe lack
of physician’s recommendation to do CRC screening [23]. In Asia Pacific region,
countries with low CRC screening participation were found to have the lowest
physician recommendation rate [21]. According to an American study, failure of a
clinician to suggest screening was identified as the most important barriers to CRC
screening [24].
The most common barrier was “unavailability of the test”. The two most com-
mon patient factors are “patient in a hurry” and “poor patient awareness”. This may
be related to the low availability of the test in the primary care setting and poor
awareness and understanding of the importance of colorectal cancer screening
among patients.
5.3 Lack of access of CRC screening
A notable category of barriers that people face that hinders them from CRC
screening participation is access barriers. One of them is financial constraints.
Another is time constraint. In a busy clinic, long patient waiting time may lead to
patient in a hurry and refusal despite being recommended. It is known that the
conventional gFOBT is troublesome and embarrassing for patients to do. Another
drawback of the test is patient has to be on certain food restriction and the test
has to be repeated at least twice. Therefore, many countries have now moving




Many stated that they were too busy, or the tests were too time consuming.
Thirdly, there is limited access to centers that provide such screening tests [23].
The most common barrier for screening is because FOBT test is unavailable in the
primary care clinic. FOBT is in fact easily available and free in certain health care
facilities but only few health clinics have this test. In most of the primary care health
clinics, the test needs to be sent to nearest hospital laboratory and because of that it
become tedious and not commonly ordered [25].
Majority of patients will come to primary care as their first consult. Wellness
clinic has been implemented in primary care clinics. This clinic is meant for patients
to come for screening. However, the programme in the certain clinic is mainly
targeting on screening cardiovascular risk factors such as diabetes, hypertension
and hypercholesterolaemia. Little is done for cancer screening. Cervical cancer
screening has the highest patient uptake (43%) because of the incorporation of Pap
smear programme in maternal and child health clinic which is run in primary care
facilities [25].
5.4 Patient’s negative perception towards CRC screening
There are many people who do not perceive that they are at risk of getting CRC.
This low perceived risk is attributable to several factors, such as not having a family
history of CRC, not experiencing any signs or symptoms, living a healthy or low-
risk lifestyle or being free from health problems in general [23]. Another barrier
that many studies report is the negative perception towards screening methods,
with a more negative view towards more invasive procedures such as endoscopic-
based procedures. Among the negative views reported were fear, pain experienced
or perceived pain towards screening procedures, feeling of embarrassment, health
damage, inconvenience and lack of confidence in screening efficacy. Fear of test
result is a common barrier for any test. It is especially when most people relate
cancer to untreatable and fatal disease. A study in Italy also showed the same
finding where being concern with the test result is the most important reason of
patient’s noncompliance.
5.5 Others factor
Throughout the world there are widespread differences in CRC screening
implementation status and strategy. Differences can be attributed to geographical
variation in CRC incidence, economic resources, healthcare structure and infra-
structure to support screening such as the ability to identify the target population at
risk and cancer registry availability. Despite well-developed CRC screening guide-
lines, implementation of screening is markedly different among countries and
regions worldwide [26]. What is more, there is also inequitable access to CRC
screening, at least in relation to socioeconomic status and ethnicity. The mecha-
nism, however, is not well understood [27].
6. Intervention related to CRC screening
Table 1 showed some evidence from previous studies on CRC screening and
intervention modalities. Mixed of intervention through telephone counseling, a
mail invitation, email/text-message reminder, health talk, video and brochure are
some intervention has been done and showed a positive finding on CRC screening
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promote it. The example from Table 1 can be part of promoting the CRC screening
using FOBT for early detection of cancer.
7. Others prevention strategies
Findings from a systematic review suggest that small media interventions (eg,
interventions using mailed materials, text messages, and telephone calls) may be
effective in improving screening uptake for breast, cervical, colorectal, and gastric
cancer in Asian countries. Therefore, there is a priority need for programs that raise
awareness about the warning signs and symptoms of cancer and the benefits of
early detection. This form of secondary prevention should be implemented in
countries in which resources for population-based screening are lacking, particu-
larly for cancers. Overall, the findings of the evaluation indicate that a culturally
adapted, evidence-based mass media intervention appears to impact positively in
terms of improving CRC symptom awareness among population; and that impact is
more likely when a campaign operates a differentiated approach that matches
modes of communication to the ethnic and religious diversity in a population.
Research shown that there was a significant improvement in the recognition of all
CRC symptoms (prompted) at follow up and a significant improvement in the
knowledge of three unprompted symptoms, i.e. ‘blood in stool’, ‘feeling that the
bowel does not empty after using the lavatory’ and ‘unexplained weight loss’.
A recommendation from a physician is the most influential factor in determin-
ing whether a patient is screened for colorectal cancer. While the vast majority of
primary care physicians report that they screen for colorectal cancer, many patients
do not receive the recommendation they need. People with a high risk for CRC
should not be included in a routine screening used for the general population. Their
screening must be started early in a shorter period, and using various tests. The
United States Preventive Task Force recommends CRC screening for the average at-
risk population, using an annual fecal occult blood test (FOBT), a periodic flexible
sigmoidoscopy (FS), or a colonoscopy [22]. One of the solutions is to engage the
primary care doctors and family physician in identifying and recommending high
risk patients for colorectal cancer screening. The effectiveness of the family doctor’s
role has been proven in previous studies and should be the way forward to increase
awareness and cancer screening uptake.
Simultaneously, concerted effort is needed to increase numbers of skill operators
and availability of the procedure throughout the country. In certain Europe coun-
tries, nurses have been trained to perform endoscopy to reduce patient’s waiting
time. On the other hand, fecal occult blood test can be utilized for mass screening
among low risk or asymptomatic patients.
All these barriers could be overcome with the implementation of government-
subsidized nationwide population screening, with the provision of more accessible
screening times such as having them available during non-working hours or non-
working days. However, even if the above-mentioned barriers have been overcome,
it would not solve the problem if the people inherently do not wish to participate
due to certain psychological barriers that are more difficult to tackle. Among these
is the fatalistic belief that their lives are in the hands of fate or God. They believe
that if it is destined that they are to have cancer, there is nothing they can do about
it and early detection of cancer would not benefit them [23].
A patient’s personal awareness of his or her risk level is important. Awareness of
the health status of family members is also needed and should be encouraged.
Awareness of discrepancies in screening rates for people in racial and ethnic groups





Public health prevention on CRC screening uptake is very important for reduc-
ing the incidence and mortality. Population will benefit more with an early CRC
screening uptake. There are multiple barriers that can hinder person from under-
going CRC screening for early prevention, detection and treatment. Majority of
these barriers encountered regarding the poor rates of CRC screening are similar
across countries in Asia, except for specific barriers that are due to unique circum-
stances. Lack of knowledge/education is the most critical barrier that is linked to a
majority of other barriers. Continuous effort is important to reduce CRC related
morbidity and mortality. Previous evidence showed positive effect on promoting
CRC screening among community. The increased uptake of CRC screening also
needs multicomponent in the intervention such as health communication, employer
as well as the commitment from the physician itself. The enhancement of
multicomponent screening programme will leads to successful rate of CRC screen-
ing uptake among the community.
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